Goldman Sachs Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Raises Target Price to $27
Olema Pharmaceuticals Analyst Ratings
JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $31
Olema Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Oppenheimer Reiterates Outperform on Olema Pharmaceuticals, Maintains $30 Price Target
Olema Pharmaceuticals Analyst Ratings
Buy Rating Reaffirmed for Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strong Financials
Buy Rating Affirmed for Olema Pharmaceuticals Amidst Promising Clinical Developments and Strategic Collaborations
Olema Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Olema Pharmaceuticals on Strong Clinical Trial Data for Palazestrant and Ribociclib Combination
Buy Rating Justified by Promising Efficacy and Safety Profile of Olema Pharmaceuticals' Drug Combination in Clinical Studies
Olema Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Olema Pharmaceuticals, Maintains $30 Price Target
Promising Clinical Trial Results Bolster Buy Rating for Olema Pharmaceuticals
Olema Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $28
Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Arcus Biosciences (RCUS)
Buy Rating on Olema Pharmaceuticals Amid Promising Clinical Trials and Strong Financial Position
Buy Rating Affirmed on Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strategic Novartis Collaboration
Promising Future for Olema Pharmaceuticals With Palazestrant in Breast Cancer Treatment: A Buy Rating